
VitriVax Secures $17.25 Million to Advance Vaccine Platform
Round led by Adjuvant Capital and RA Capital will enable scale-up of key clinical and regulatory operations VitriVax a vaccine formulation technology company, announced it
Round led by Adjuvant Capital and RA Capital will enable scale-up of key clinical and regulatory operations VitriVax a vaccine formulation technology company, announced it
Funding to accelerate development of next-generation intravascular ultrasound platform and support FDA clearance for U.S. market launch Evident Vascular, Inc., a medical technology company developing